CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 95 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2020. The put-call ratio across all filers is 0.41 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $195,092,582 | -18.9% | 7,089,120 | +0.0% | 0.02% | -15.0% |
| Q2 2023 | $240,491,429 | -52.8% | 7,087,870 | -50.0% | 0.02% | -13.0% |
| Q1 2023 | $509,554,372 | +61.8% | 14,162,156 | +100.5% | 0.02% | -25.8% |
| Q4 2022 | $314,885,891 | +59.7% | 7,064,974 | +0.7% | 0.03% | +47.6% |
| Q3 2022 | $197,215,000 | +4.3% | 7,015,843 | +0.0% | 0.02% | +10.5% |
| Q2 2022 | $189,074,000 | -20.8% | 7,013,144 | +0.0% | 0.02% | 0.0% |
| Q1 2022 | $238,769,000 | -11.7% | 7,010,253 | +0.2% | 0.02% | -5.0% |
| Q4 2021 | $270,464,000 | -10.8% | 6,999,580 | +24.7% | 0.02% | -16.7% |
| Q3 2021 | $303,172,000 | +2375.3% | 5,615,333 | +1433.0% | 0.02% | +2300.0% |
| Q2 2021 | $12,248,000 | +76.0% | 366,295 | +8.4% | 0.00% | 0.0% |
| Q1 2021 | $6,961,000 | – | 337,900 | +33789900.0% | 0.00% | – |
| Q4 2020 | $0 | -100.0% | 1 | -98.6% | 0.00% | – |
| Q3 2020 | $1,000 | – | 73 | +46.0% | 0.00% | – |
| Q4 2019 | $0 | – | 50 | +150.0% | 0.00% | – |
| Q3 2019 | $0 | – | 20 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,605,390 | $71,552,232 | 10.98% |
| Octagon Capital Advisors LP | 761,398 | $33,935,509 | 5.28% |
| TSP Capital Management Group, LLC | 269,895 | $12,029,225 | 4.50% |
| Redmile Group, LLC | 1,977,451 | $88,134,991 | 3.60% |
| COMMODORE CAPITAL LP | 495,823 | $22,099 | 3.33% |
| Tri Locum Partners LP | 176,109 | $7,849,000 | 3.18% |
| ACUTA CAPITAL PARTNERS, LLC | 115,000 | $5,125,550 | 3.15% |
| Ikarian Capital, LLC | 267,476 | $11,921,406 | 2.88% |
| RTW INVESTMENTS, LP | 3,084,215 | $137,463,463 | 2.81% |
| Eversept Partners, LP | 558,774 | $24,904,557 | 2.18% |